GE HealthCare announces Flyrcado milestone: Strong pilot results drive broader rollout at CVAUSA

GE HealthCare announced that Cardiovascular Associates of America (CVAUSA), the largest network of private cardiology groups in the U.S., plans to broaden its adoption of GE HealthCare’s FDA-approved cardiac positron emission tomography (PET) radiotracer Flyrcado™ (flurpiridaz F 18) injection, across approximately 25 sites following a successful pilot at Cardiovascular Medicine in Davenport, Iowa. This planned rollout marks a significant milestone for advancing PET myocardial perfusion imaging (MPI) in community cardiology settings and reflects growing confidence in Flyrcado’s role in shaping the future of cardiac imaging.

The pilot at Cardiovascular Medicine provided cardiologists with an opportunity to evaluate Flyrcado in real-world workflows.

“We are encouraged by the adoption of Flyrcado in a variety of real-world settings—including large academic institutions, integrated delivery networks (IDNs), mobile PET/CT settings, and customers transitioning from SPECT to PET MPI,” said Eric Ruedinger, Vice President and General Manager of GE HealthCare’s Pharmaceutical Diagnostics division for the U.S. and Canada. “The accumulating real-world evidence shows Flyrcado’s versatility and efficacy across diverse clinical environments, laying the foundation for continued growth and confidence in this game-changing tracer.”

Recent milestones underscore the growing importance of Flyrcado in clinical practice. GE HealthCare announced a distribution and services agreement with CDL Nuclear Technologies to support implementation across multiple sites of care, including private cardiology practices.